Alterations of cellular G proteins have been implicated in the pathophysiology of some psychiatric disorders. So far, no study assessed G protein function in anorexia nervosa (AN) and bulimia nervosa (BN). Therefore, we measured immunoreactive levels of G as , G ai , G aq/11 and G b protein subunits in mononuclear leukocytes of 71 drug-free women, including 25 subjects with AN, 26 individuals with BN and 20 healthy controls. As compared to healthy women, anorexic patients exhibited significantly increased levels of G ai and G b proteins, while bulimic patients had significantly increased levels of G as , G ai and G b proteins. Immunoreactive levels of peripheral G protein subunits were not significantly correlated with demographic or nutritional parameters. These findings, although obtained in peripheral blood cells, may suggest a derangement of G protein-mediated signal transduction in the pathophysiology of eating disorders.
Abnormalities in signal transduction pathways have been demonstrated in a variety of human diseases. 1, 2 Part of these alterations consists of dysfunctions of guanine nucleotide binding proteins (G proteins) that are key elements in the transmission of signal from membrane receptors to effector proteins.
Heterotrimeric G proteins are localized in the inner surface of the plasma membrane and consist of an a subunit, which binds and hydrolyses guanine triphosphate, and b and g subunits, which form a tightly but noncovalently linked dimer. 1 The family of G proteins is a crucial point of convergence in the transmission of signals from a variety of hormone and neurotransmitter membrane receptors to a series of downstream intracellular events. It has been estimated that about 80% of all known hormones and neurotransmitters elicit cellular response through G proteins coupled to a variety of intracellular second messengers, effector enzymes and ionic channels. 1 In the central nervous system (CNS), the ability of many G proteins to interact with multiple receptors provides an efficient mechanism for the neuron to organize, integrate and amplify signals from a large number of neurotransmitter pathways. Therefore, in view of their critical role in signal processing, it seems likely that both qualitative and quantitative dysfunctions of G proteins may lead to altered CNS functions and disturbed behaviours.
Recently, evidence has been provided that alterations in either the levels and/or the function of the a subunit of the stimulatory G protein (G as ) occur in peripheral cells from subjects with bipolar disorders. [3] [4] [5] [6] [7] Similarly, modifications in the various subunits of G proteins have been demonstrated in both the periphery and the CNS of schizophrenic patients, [8] [9] [10] whereas no change has been detected in patients with panic disorder. 11 An increasing body of evidence also suggests that psychotropic drugs, upon chronic administration, may exert effects at postreceptor sites, in particular, at the level of G proteins. 2 To the best of our knowledge, no study explored so far the functional status of the signal-transducing G proteins in patients with anorexia nervosa (AN) or bulimia nervosa (BN). These disorders are characterized by multiple neurotransmitter and neurohormone alterations, concomitant depressive and anxious symptoms, and several malnutrition-induced physiological aberrations. Furthermore, it is known that most of the neurotransmitters and neuropeptides implicated in the modulation of eating behaviour and energy homeostasis act through G proteincoupled membrane receptors. Therefore, the assessment of G proteins in patients with eating disorders seems to be of great interest.
In the present study, we measured the levels of G protein subunits mediating stimulation and inhibition of adenylyl cyclase (G as and G ai , respectively), or stimulation of phosphoinositide turnover (G aq/11 ) or involved in the anchorage of the catalytic subunit to membrane receptors (G b ) in mononuclear leukocytes (MNL) from a group of untreated symptomatic patients with AN or BN and a healthy comparison group.
Methods

Subjects
A total of 71 women were recruited for the study. They were 51 outpatients attending the Eating Disorder Center of our Department and 20 healthy controls. According to DSM-IV criteria, 25 patients fulfilled the diagnosis of AN and 26 the diagnosis of BN. Diagnostic assessment was made by a trained interviewer using the structured clinical interview (SCID) for DSM-IV. 12 Of the AN women, 15 were exclusively food restrictors and 10 occasionally binged and/or purged with a frequency no greater than twice a week. At the time of the study, two anorexics had a concomitant diagnosis of major depression. Patients with BN were all of the purging subtype, with binge episodes always followed by selfinduced vomiting; two of these patients also abused laxatives, six exercised excessively and four had a positive history of AN. All AN women and two bulimics were amenorrheic; three bulimics were oligomenorrheic; the remaining patients had normal regular menses.
At the time of the study, some patients had never taken psychotropic medications (15 anorexics and 18 bulimics); the remaining ones had been drug free for more than 6 weeks. None was taking nonpsychotropic medications for at least 4 weeks or abused alcohol in the last 4 weeks. All of them were studied before entering specific treatment programmes.
Control women were mentally healthy, as assessed by a clinical interview, and had no positive family history of mental disorders as assessed by the Family History Research Diagnostic Criteria. 13 Clinical interviews were performed by an experienced psychiatrist trained in the use of several psychiatric interviews including the SCID; he paid particular attention to rule out present or past histories of eating disorders in these subjects. Healthy controls were regularly menstruating and had normal diets; all of them had been drug free for more than 4 weeks and had never abused alcohol.
Both patients and controls had normal physical examinations, normal values on routine laboratory tests and normal electrocardiograms. Female controls and patients who were normally menstruating were tested in the follicular phase of their menstrual cycle (days 5-10 from menses). The follicular phase was chosen to avoid having to monitor the ovulation in our outpatients. No subject was taking oral contraceptives or had a past history of alcohol or drug abuse.
Procedure
Subjects gave written informed consent prior to study participation. Patients underwent a psychopathological assessment by means of the eating disorder inventory (EDI) 14 and the bulimic investigation test Edinburgh (BITE) 15 to evaluate the eating-related psychopathology. In each subject, body weight (BW) and height were measured, and the body mass index (BMI) was calculated. Moreover, in 14 healthy controls, 12 anorexics and 11 bulimics, body composition was evaluated by means of a bioelectrical impedance analyser (STA/BIA, Akern Srl, Florence, Italy).
MNL isolation
After an overnight fast, blood samples (60 ml) were collected by venipuncture in the morning (between 08:00 and 10:00 am) into a heparinized glass tube and processed immediately. MNL were isolated using Ficoll-Hypaque gradient. Mononuclear cells were washed with phosphate-buffered saline, lysed mechanically in AT buffer (60 mM KCl, 150 mM NaCl, 14 mM b-mercaptoethanol, 2 mM EDTA, 15 mM Hepes, pH 7.9, 0.3 sucrose, 5 mg/ml aprotinin, 10 mg/ ml leupeptin, 2 mg/ml pepstatin and 1% Triton X-100) and frozen at À801C until assayed.
Immunoblot analysis
On the day of assay, samples were thawed and the extracts were centrifuged at 100 000 Â g for 30 min at 41C. Protein concentration was determined according to the method of Bradford. 16 The linearity of protein concentration for Western blotting was ascertained by resolution of selected quantity of protein (between 5 and 50 mg). Subsequent assays were performed using a protein concentration within the linear range for immunolabelling of G protein subunits. An aliquot of 20 mg of proteins, in duplicate for each subject, was separated by 12% sodium dodecyl sulphate polyacrylamide gel electrophoresis and transferred to nitrocellulose filter (0.45 mm Schleicher & Shuell). Blots were washed in TBS-T (10 mM Tris-HCl, pH 8.0, 150 mM NaCl, 0.05% Tween 20) and blocked by incubation with 5% nonfat dry milk in TBS-T (blocking buffer). After three washes in TBS-T, blots were incubated in blocking buffer overnight with each of the following policlonal antibodies directed specifically against G as , G aiÀ3 , G aq/11 , G b (all diluted 1 : 100) (Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA) and antiactin monoclonal antibody (dilution 1 : 5000) (SigmaAldrich Corp, St. Louis, MO, USA). After being washed by TBS-T, blots were incubated with the secondary antibody, horseradish peroxidase-linked anti-rabbit IgG (Amersham Pharmacia Biotech, Buckinghamshire, England), in blocking buffer for 1 h. Labelled blots were washed with TBS-T and immunoreactivity was detected with Enhanced Chemiluminescence Western Blot detection System (Amersham Pharmacia), followed by exposure to Kodak X-Omat film (Kodak, Rochester, NY, USA).
Quantification of immunoblots was performed by a densiometric scanning of the autoradiograms using an image analysis system. An aliquot of pooled standard leukocyte proteins were run on one lane of every gel to minimize the interassay variation. The optical density units obtained from each subject were normalized against those of pooled standard leukocyte proteins. Furthermore, the optical density of each G protein band was normalized against respective actin immunoreactivity band to reduce the inter-lane variation.
Although anti-G as detects both 52-and 45-kDa Ga s species, only 45-kDa species is detected in leukocytes. The other G protein subunits were found to migrate at the expected molecular weight.
Statistical analysis
The BMDP statistical software package 17 was used for data analysis. Data distributions were examined for normality and homogeneity of variance. Since G protein values resulted normally distributed, differences among the groups were analysed by one-way analysis of variance (ANOVA) and the post hoc Tukey's test. Relation between G protein measures and clinical or nutritional variables were assessed by stepwise multiple regression tests and Pearson's correlation test, where appropriate.
Results
Clinical and demographic characteristics of the study sample are shown in Table 1 . Statistically significant inter-group differences emerged in nutritional parameters, with anorexics showing significantly decreased BW, BMI, body fat mass and body lean mass as compared to healthy controls. Bulimic subjects, instead, did not significantly differ from controls in these parameters. Moreover, bulimic patients scored significantly higher than anorexics on the BITE total score and on the bulimia and maturity fear EDI subitem scores, but significantly lower on the interpersonal distrust subitem score of the EDI.
One-way ANOVA showed significant inter-group differences in the immunoreactive levels of MNL G as (F 2, 68 ¼ 4.14, P ¼ 0.02), G ai (F 2, 68 ¼ 11.65, P ¼ 0.0001) and G b (F 2, 68 ¼ 12.44, P ¼ 0.0001), but not in G aq/11 (F 2, 68 ¼ 2.31, P ¼ 0.1). Indeed, as compared to healthy women, anorexic patients exhibited significantly increased values of G ai and G b proteins in peripheral MNL, while bulimic subjects had significantly enhanced values of peripheral MNL G as , G ai and G b protein subunits (Figure 1) . These results did not change when the two anorexics with comorbid major depression or the four bulimics with positive history of AN were excluded from the analyses. Moreover, no significant differences emerged in MNL levels of both G as, G ai, G aq/11 and G b between pure restrictor and binge-purging anorexics.
Given the significant differences in age and BMI across the three study groups, correlation analyses were performed between MNL levels of G protein subunits and those variables in each subject group. No statistically significant correlation emerged between peripheral levels of G as , G ai , G aq/11 and G b and subjects'age or BMI in both healthy controls and anorexic or bulimic patients.
To investigate the simultaneous influence of nutritional variables on immunoreactive levels of MNL G Po0.007 vs anorexic women. *N=14 subjects, **N=12 subjects, ***N=11 subjects.
G proteins in eating disorders P Monteleone et al protein subunits, a stepwise multiple regression analysis was carried out in the subgroup of subjects who had a nutritional assessment. BW, BMI, body fat mass and body lean mass were independent variables and immunoreactive levels of G protein subunits were dependent variables. This analysis showed that immunoreactive levels of the MNL G as , G ai, G aq/11 and G b proteins were not significantly associated with nutritional variables.
Discussion
To our knowledge, this is the first study aiming to explore G protein function in patients with eating disorders. We found that drug-free underweight anorexic women exhibited significantly enhanced immunoreactive levels of G ai and G b protein subunits in peripheral MNL, while drug-free symptomatic bulimics showed significantly increased levels of MNL G as , G ai and G b protein subunits. No significant change in the MNL G q/11 subunit occurred in both groups of patients. These results suggest that, in symptomatic patients with AN or BN, signalling through receptors linked to G as and G ai is altered, whereas the signal transduction involving stimulation of phosphoinositide turnover through G aq/11 protein subunit is preserved. G as and G ai protein subunits are coupled to different types of membrane receptors, including those for serotonin, dopamine, noradrenaline, neuropeptide Y, leptin, orexins and some other neurotransmitters and neuropeptides involved in the modulation of eating behaviour, energy homeostasis or important physiological functions, such as mood, cognition, anxiety and aggression. Therefore, changes in G as and G ai protein subunits may represent a pathophysiological mechanism accounting for multiple neurotransmitter alterations and concomitant physiological and psychopathological aberrations occurring in both AN and BN. The G b protein subunit is part of the bg complex, which is involved in the coupling of heterotrimeric G proteins to membrane receptors. Nonetheless, there is evidence that the bg complex plays an important role in the regulation of certain intracellular effectors, adenylyl cyclase included. 1 Therefore, in AN and BN, alterations of G b proteins may also have prominent pathophysiological implications.
The mechanisms underlying alterations in G protein levels in MNL of eating disorder patients are unknown. Changes in nutritional parameters, such as decreases of BW or body fat mass, did not seem to influence MNL G protein measures in our patients, since no significant relation was found between these variables. This finding sounds consistent with the reported observation that, in obese people, BW loss was not associated with significant changes in the concentrations of both G as and G ai protein subunits, although these results were obtained in a different cell population, that is, subcutaneous adipocytes. 18 It has been demonstrated that changes in endogenous hormones, such as glucocorticoids, estrogens and thyroid hormones, may alter G protein function. [19] [20] [21] AN and BN are characterized by malnutrition-induced alterations in hypothalamic-pituitary-adrenal axis activity and thyroid and gonadal functions; 22, 23 hence, the possibility exists that malnutrition-induced modifications of endogenous cortisol, 17b-estradiol and thyroid hormones are responsible for the observed changes in MNL immunoreactive levels of G proteins in our patients. Moreover, evidence indicates the existence of neural-mediated immunomodulatory mechanisms involving the sympathetic and parasympathetic innervation of primary and secondary lymphoid organs. 24 These mechanisms may modulate MNL G proteins. Altered autonomic functions occur in AN and, to a lesser degree, in BN; 25, 26 thus, MNL G protein alterations in our anorexic and bulimic patients may reflect secondary influences of altered autonomic innervation of lymphoid organs. Finally, changes in G protein levels may represent secondary adaptive modifications to disease-related alterations in endogenous receptor ligands. Further studies need to clarify whether the results presented here are primary disease-related changes or reflect adaptive responses consequent to other dysfunctions induced by the disordered eating behaviours of AN and BN patients.
The increases of peripheral immunoreactive levels of G as and/or G ai are not peculiar of patients with AN or BN, since similar alterations have been reported in subjects with bipolar disorder, 3, 4 major depression 27 and schizophrenia, 10 in men at high risk for alcoholism 28 and in opioid addicts. 29 Therefore, the major challenge for future studies will be to elucidate the mechanisms by which shared peripheral abnormalities of G proteins might be involved in the pathophysiology of different psychiatric disorders. The involvement of G proteins in the pathophysiology of eating disorders as implicated from present data should be taken with caution, since findings obtained in peripheral blood cells cannot be directly extrapolated to the CNS. Indeed, with respect to brain neurons, peripheral blood cells are exposed to a potentially completely different environment, which may lead to substantial differences in G protein function. Therefore, with this limitation in mind, we can conclude that AN and BN are associated with increased MNL immunoreactive levels of certain G protein subunits, which may be potentially involved in the pathophysiology of eating disorders. The primary or secondary nature of these changes remains to be determined.
